Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast for higher-risk community COVID-19 patients in Dutch primary care
NL-OMON58921Phase 4Withdrawn
- Sponsor
- Maastricht University
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of montelukast in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Maastricht University. Primary endpoint: Time to recovery. Planned start Oct 2022; status: withdrawn.
02
Drugs
montelukast
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON58921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58921.